HER2+转移性乳腺癌患者的长期生存或与调节性T细胞活性相关。HER2阳性（HER2+）乳腺癌约占全部乳腺癌的15%-20%，患者预后往往较差[1]。尽管曲妥珠单抗联合化疗能够显著改善患者的疗效和延长生存期（OS），但大多数患者会发生疾病进展[2,3 ...

PathAI's AIM-IHC Breast Panel is designed to address key challenges in breast cancer biomarker quantification, particularly the need for precise and reproducible assessment. The panel provides ...

New DESTINY-Breast06 analysis showed trastuzumab deruxtecan doubled PFS versus chemotherapy in patients with rapid ...

The HER2-low and HER2-ultralow breast cancer subtype designations have led to a changed landscape in HER2-directed therapies, ...

The analysis was performed on independent study sets of HER2-positive and negative/low breast cancers, already analyzed by central immunohistochemistry (IHC) and FISH testing. Phospho-HER2 and ...

Breast cancer classed as HER2-positive – defined as an immunohistochemical (IHC) score of three or more – accounts for somewhere between 20% to 25% of all patients with the disease.

A key benefit of IHC in cancer studies is its ability to offer visual context for tumors and their surrounding microenvironment, uncovering unique insights that can guide appropriate therapeutic ...

Therapies for EBV-positive posttransplant lymphoproliferative disease, breast cancer, Barth syndrome, pain, and migraine are under review.

Immunohistochemistry (IHC) is an essential tool in oncology, enabling pathologists to detect and quantify protein expression which in turn guides decisions for systemic therapy. However, while several ...

IHC 1+, or IHC 2+/in situ hybridization [ISH]-) breast cancer who have received prior systemic therapy for unresectable or metastatic disease. Dato-DXd is a specifically engineered TROP2-directed ...